Search Results
Pfizer exec Amy Schulman talks gender, power and company policy
In an interview with The New York Times, Pfizer SVP and General Counsel Amy Schulman has some advice for ambitious women. Soon to lead a new vaccines, oncology and consumer health division at Pfizer ($PFE), Schulman says ambitious women need to speak up, spend their political capital and stop asking ...
WHO pushes for removal of mercury from medical devices; Boston Scientific gears up for Q3 results;
Sanger Institute taps DDN to help with Big Data boom. Article > Venter outlines plan to print vaccines ...
Merck KGaA scouts for deep-pocketed partners to leverage its R&D budget
KGaA right the R&D ship Merck KGaA doubles down on Oncothyreon's failed cancer vaccine Merck ...
Venter outlines plan to print vaccines on Mars
the printer being used to send vaccines to Mars. Interview ...
Sanger Institute taps DDN to help with Big Data boom
Lustre file system, they have now adopted DDN's EXAScaler parallel file system appliance for half ...
Icon deepens adaptive trial work with patient-safety service
for time-consuming reviews of individual patient files and allows researchers to take a broad view of study ...
UPDATED: CardioDx to hit public markets with planned $86.2M IPO
filing. CardioDx wants to use the money to expand its commercialization efforts, boost research ...
Vital Therapies plots $86M IPO as biotech market boils
billion. Including Vital Therapies, there are at least 12 companies with S-1 filings waiting in the wings, ...
Novartis whacks vaccine jobs as it eyes unit for disposal
that the vaccines and diagnostics unit, along with others, is on the table for possible divestiture. In a note ...
Celladon, Xencor bid for $155M in red-hot IPO market
Xencor's filing Special Reports: Foundation Medicine, Ophthotech go gangbusters in 2013 biotech IPO revival ...
